Neo Kuma’s Psychedelic Bet Is Starting to Pay Off
For psychedelic investors, finding the next breakthrough company is the difficult part. Neo Kuma Ventures appears to have made at ...
For psychedelic investors, finding the next breakthrough company is the difficult part. Neo Kuma Ventures appears to have made at ...
Definium Therapeutics has reported positive Phase III results for its LSD-based medicine DT120 in generalised anxiety disorder, giving the company ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
